Recurrence-Related Factors of Medication-Related Osteonecrosis of the Jaw: A Five-Year Experience-Reference-Cited by-同舟云学术

Recurrence-Related Factors of Medication-Related Osteonecrosis of the Jaw: A Five-Year Experience

Published:2021-12 Issue:12 Volume:79 Page:2472-2481
ISSN:0278-2391
Container-title:Journal of Oral and Maxillofacial Surgery
language:en
Short-container-title:Journal of Oral and Maxillofacial Surgery

Author:

Chen Shuo,Ren Hongyu^ORCID,He Yang,An Jingang,Zhang Yi

Publisher

Elsevier BV

Subject

Otorhinolaryngology,Oral Surgery,Surgery

Reference29 articles.

1. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment;Nicolatou-Galitis;Oral Surg Oral Med Oral Pathol Oral Radiol,2019

2. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update;Ruggiero;J Oral Maxillofac Surg,1938

3. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws;J Oral Maxillofac Surg,2007

4. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws;Freiberger;J Oral Maxillofac Surg,2009

5. A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration;Ohbayashi;Osteoporos Int,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevention of medication-related osteonecrosis of the jaw in mice by adipose-derived stem cells associated with activated autophagic flux;Journal of Dental Sciences;2024-10

2. Efficacy of submental island flap closing advanced mandibular MRONJ lesion in malignancy patients;Head & Neck;2024-06-08

3. Examination of certain single-nucleotide polymorphisms of interleukins 1A and 1B in medication-related osteonecrosis of the jaw — An ambirectional cohort study;Journal of Cranio-Maxillofacial Surgery;2024-06

4. Medication-related osteonecrosis of the jaws associated with the use of bone-modifying agents;Stomatologiya;2024

5. Osteonecrosis in the context of denosumab - Perspective of the bone metabolism specialist and the maxillofacial specialist;Revista de Osteoporosis y Metabolismo Mineral;2024